Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Revenue (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Revenue for 4 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 38.48% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.8 million, a 27.66% decrease, with the full-year FY2024 number at $9.4 million, up 269.68% from a year prior.
  • Revenue was $1.4 million for Q3 2025 at bioAffinity Technologies, up from $1.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.4 million in Q1 2024 to a low of -$399265.0 in Q2 2022.
  • A 4-year average of $1.1 million and a median of $1.4 million in 2025 define the central range for Revenue.
  • Peak YoY movement for Revenue: soared 261180.24% in 2024, then plummeted 47.05% in 2025.
  • bioAffinity Technologies' Revenue stood at $2346.0 in 2022, then soared by 94245.95% to $2.2 million in 2023, then fell by 0.26% to $2.2 million in 2024, then crashed by 34.5% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Revenue are $1.4 million (Q3 2025), $1.3 million (Q2 2025), and $1.9 million (Q1 2025).